Legend Biotech ( NASDAQ:LEGN ) Full Year 2024 Results Key Financial Results Revenue: US$627.2m (up 120% from FY 2023... Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales ...
Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat reports. One ...
5 analysts have shared their evaluations of Legend Biotech (NASDAQ:LEGN) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their ...
Hosted on MSN1mon
Is Legend Biotech (LEGN) the Best Mid-Cap Growth Stock to Buy According to Analysts?In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands against other best mid-cap growth stocks to buy according to analysts. Investing in mid-cap ...
Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating ...
Legend Biotech (NASDAQ:LEGN – Get Free Report) had its target price dropped by analysts at Morgan Stanley from $82.00 to ...
SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ...
There are more milestones ahead that will potentially make CARVYKTI available to even more patients,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "CARVYKTI has already helped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback